Lexiscan

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cardiovascular Diseases

Conditions

Cardiovascular Diseases, Coronary Artery Disease

Trial Timeline

Feb 9, 2016 → Jun 14, 2018

NCT ID

NCT03103061

About Lexiscan

Lexiscan is a phase 2 stage product being developed by Astellas Pharma for Cardiovascular Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT03103061. Target conditions include Cardiovascular Diseases, Coronary Artery Disease.

What happened to similar drugs?

9 of 20 similar drugs in Cardiovascular Diseases were approved

Approved (9) Terminated (2) Active (9)

🔄polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3

🔄Dulaglutide + PlaceboEli LillyPhase 3

🔄raloxifene + placeboEli LillyPhase 3

🔄Orforglipron + PlaceboEli LillyPhase 3

✅Rosuvamibe + MonorovaYuhanApproved

✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved

✅Rosuvamibe + MonorovaYuhanApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03103061	Phase 2	Completed	Feb 9, 2016	Jun 14, 2018	Cardiovascular Diseases
NCT01085201	Phase 1	Completed	Apr 1, 2010	Mar 1, 2013	Sickle Cell Disease

Competing Products

20 competing products in Cardiovascular Diseases

See all competitors

Product	Company	Stage	Hype Score
polypill + Usual cardiovascular medications	Dr. Reddy's Laboratories	Phase 3	37
Dulaglutide + Placebo	Eli Lilly	Phase 3	40
raloxifene + placebo	Eli Lilly	Phase 3	40
Evacetrapib	Eli Lilly	Phase 1	29
Orforglipron + Placebo	Eli Lilly	Phase 3	47
Prasugrel (CS-747) + Clopidogrel	Eli Lilly	Phase 2	35
Rosuvamibe + Monorova	Yuhan	Approved	39
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin	Yuhan	Approved	43
Rosuvamibe + Monorova	Yuhan	Approved	43
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)	Daiichi Sankyo	Approved	43
mirabegron + tamsulosin	Astellas Pharma	Phase 1	29
TRC150094	Torrent Pharmaceuticals	Phase 1/2	32
Lorcaserin hydrochloride + Placebo	Eisai	Approved	43
Lepodisiran Sodium + Placebo	Eli Lilly	Phase 3	44
Retatrutide + Placebo	Eli Lilly	Phase 3	44
Empagliflozin + Placebos	Eli Lilly	Approved	43
Evacetrapib + Placebo	Eli Lilly	Phase 3	32
Placebo + AZD0780	AstraZeneca	Phase 2	35
Risk of low dose aspirin discontinuation	AstraZeneca	Pre-clinical	26
Midazolam + AZD5718	AstraZeneca	Phase 1	29